Survival in patients with limited-stage peripheral T-cell lymphomas

Robert Briski, Andrew L. Feldman, Nathaniel G. Bailey, Megan S. Lim, Kay Ristow, Thomas M. Habermann, William R. Macon, David J. Inwards, Joseph P. Colgan, Grzegorz S. Nowakowski, Mark S. Kaminski, Thomas E. Witzig, Stephen M. Ansell, Ryan A. Wilcox

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


The natural history of limited-stage peripheral T-cell lymphoma (PTCL) remains poorly defined. Therefore, we examined outcomes in patients with the most common PTCL subtypes (PTCL, not otherwise specified [PTCL, NOS], angioimmunoblastic T-cell lymphoma [AITL], anaplastic large cell lymphoma [ALCL]) and limited-stage disease. In this retrospective, multicenter study, 75 patients with limited-stage disease were identified. The median event-free survival (EFS) and overall survival (OS) observed were 2.1 and 6.5 years, respectively. In a landmark analysis excluding patients with primary refractory disease, no significant benefit was observed for patients undergoing consolidative radiation therapy. With the exception of patients undergoing salvage hematopoietic stem cell transplant, survival following disease relapse or progression was poor, thus highlighting the need for improved therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)1665-1670
Number of pages6
JournalLeukemia and Lymphoma
Issue number6
StatePublished - Jun 1 2015


  • Peripheral T-cell lymphoma
  • Prognosis
  • Radiation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Survival in patients with limited-stage peripheral T-cell lymphomas'. Together they form a unique fingerprint.

Cite this